當地是全球最先進的醫療保健系統之一，現在引進這個迄今應用於 75 個國家近 25 萬次治療的強大的血液淨化技術，用於治療危疾和心臟手術患者新澤西州，普林斯頓, June 26, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO) 是透過其專屬的聚合物吸附技術使用血液淨化在深切治療部和心臟手術治療致命病症的領導者，現宣布CytoSorb®在台灣獲得食品藥物管理署 (TFDA) 的監管批准。獲核准的適應症包括從患者血液循環中藉由體外去除細胞因子（例如細胞激素風暴、敗血症）、膽紅素（例如肝病）和肌紅蛋白（例如創傷）。 心胸外科手術期間停用抗血栓藥物 Brilinta®（替格瑞洛，阿斯特捷利康）和 Xarelto®（利伐沙班，楊森/拜耳）亦獲得批准，目的是減少手術前後出血。CytoSorb 將由 Hemoscien Corporation 分銷至全台灣。 CytoSorbents 國際經銷商銷售副總裁 Bettina Sabisch 女士表示：「我們很高興宣布這個里程碑，彰顯我們 CytoSorb 療法的價值和功效，而這是經歷漫長而複雜的審 ...

Ms. Bettina Sabisch, Vice President of International Distributor Sales at CytoSorbents stated, "We are thrilled to announce this milestone which underscores the value and efficacy of our CytoSorb therapy and was achieved after navigating a long and complex approval process. We look forward to collaborating with Hemoscien and leveraging their long-standing customer relationships in Taiwan to bring this innovative therapy to patients in need." In addition to Taiwan, CytoSorb is approved in the European Union ...

The PuriFi peristaltic blood pump features a number of differentiating innovations that separate it from other standard hemoperfusion pumps including a pre-assembled adult and pediatric blood line kit, auto-priming, an auto-leveling bubble catcher, an intuitive touchscreen graphical user interface with a step-by-step user-friendly set-up guide, optional blood warming, and a rapid 10-minute set-up time. Together, these unique features enable an easy and rapid way to administer CytoSorbents' leading CytoSorb® ...

PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it will host its 2024 Virtual Annual Stockholders Meeting tomorrow, June 6, 2024 at 10 AM EDT. CytoSorbents Corporation Virtual Annual Stockholder Meeting When: Thursday, June 6, 2024, at 10:00 ΑΜ EDT Webcast: www.virtualshareholdermeeting.com/CTSO2024 Kathleen Bloch, CFO 30 ...

CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its lead product, CytoSorb®, is approved in the European Union and distributed in 75 countries worldwide. It is an extracorporeal cytokine adsorber that reduces "cytokine storm" or "cytokine release syndrome" in common critical illnesses that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death ca ...

PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the recent data presentation entitled "Early CABG with Intraoperative Haemoadsorption in Patients on Ticagrelor: The Safe and Timely Antithrombotic Removal (STAR) Registry," at the international EuroPCR 2024 conference in Paris, Fr ...

Cytosorbents Corporation (NASDAQ:CTSO) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Eric Ribner - Investor Relations Phil Chan - Chief Executive Officer Vincent Capponi - President and Chief Operating Officer Kathleen Bloch - Chief Financial Officer Makis Deliargyris - Chief Medical Officer Christian Steiner - Executive Vice President, Sales and Marketing Christopher Cramer - Senior Vice President, Business Development Conference Call Participants Yuan Zhi - B. Riley Securiti ...

Table of Contents SECURITIES AND EXCHANGE COMMISSION FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 (Exact name of registrant as specified in its charter) Delaware 98-0373793 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) | --- | -- ...

PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that it will host a virtual Key Opinion Leader and Analyst-Investor Day on Monday, May 6, 2024 from 11:30 AM to 1:30 PM ET. To register, click here. The program will cover the significant challenge of severe perioperative blee ...

PRINCETON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that topline results from its pivotal U.S. and Canadian Safe and Timely Antithrombotic Removal of Ticagrelor (STAR-T) randomized controlled trial will be featured as a late-breaking clinical trial presentation at the 104th A ...